Zacks: Analysts Anticipate Replimune Group Inc (NASDAQ:REPL) to Post -$0.36 Earnings Per Share

Brokerages expect that Replimune Group Inc (NASDAQ:REPL) will report earnings per share (EPS) of ($0.36) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Replimune Group’s earnings, with the lowest EPS estimate coming in at ($0.50) and the highest estimate coming in at ($0.29). Replimune Group reported earnings per share of ($0.26) in the same quarter last year, which would suggest a negative year-over-year growth rate of 38.5%. The business is expected to report its next quarterly earnings results on Wednesday, November 13th.

According to Zacks, analysts expect that Replimune Group will report full year earnings of ($1.50) per share for the current fiscal year, with EPS estimates ranging from ($2.03) to ($1.21). For the next year, analysts anticipate that the business will post earnings of ($1.41) per share, with EPS estimates ranging from ($1.69) to ($1.25). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that that provide coverage for Replimune Group.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.30) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.02.

Several equities research analysts have commented on the company. ValuEngine upgraded Replimune Group from a “hold” rating to a “buy” rating in a research report on Monday. Zacks Investment Research upgraded Replimune Group from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a research report on Wednesday, July 3rd. Wedbush assumed coverage on Replimune Group in a research report on Wednesday, April 24th. They issued an “outperform” rating and a $24.00 price objective on the stock. HC Wainwright assumed coverage on Replimune Group in a research report on Monday, July 8th. They issued a “buy” rating and a $26.00 price objective on the stock. Finally, Chardan Capital restated a “buy” rating and issued a $28.00 price objective on shares of Replimune Group in a research report on Thursday. Six equities research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus target price of $24.00.

A number of institutional investors have recently added to or reduced their stakes in the business. Redmile Group LLC lifted its position in shares of Replimune Group by 1.1% during the 1st quarter. Redmile Group LLC now owns 2,212,456 shares of the company’s stock valued at $33,674,000 after buying an additional 23,499 shares in the last quarter. BlackRock Inc. lifted its position in shares of Replimune Group by 8.2% during the 2nd quarter. BlackRock Inc. now owns 1,015,225 shares of the company’s stock valued at $14,883,000 after buying an additional 76,540 shares in the last quarter. Foresite Capital Management III LLC lifted its position in shares of Replimune Group by 4.0% during the 2nd quarter. Foresite Capital Management III LLC now owns 779,656 shares of the company’s stock valued at $11,430,000 after buying an additional 30,002 shares in the last quarter. Emerald Mutual Fund Advisers Trust lifted its position in shares of Replimune Group by 0.5% during the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 711,770 shares of the company’s stock valued at $10,435,000 after buying an additional 3,650 shares in the last quarter. Finally, Emerald Advisers LLC lifted its position in shares of Replimune Group by 7.1% during the 1st quarter. Emerald Advisers LLC now owns 697,898 shares of the company’s stock valued at $10,622,000 after buying an additional 46,428 shares in the last quarter. Institutional investors and hedge funds own 59.59% of the company’s stock.

Shares of NASDAQ:REPL opened at $10.40 on Tuesday. Replimune Group has a twelve month low of $8.88 and a twelve month high of $23.55. The company’s 50 day moving average is $12.73 and its 200 day moving average is $13.70. The company has a current ratio of 14.26, a quick ratio of 14.26 and a debt-to-equity ratio of 0.05. The company has a market cap of $331.86 million and a PE ratio of -7.82.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Further Reading: What is a Market Correction?

Get a free copy of the Zacks research report on Replimune Group (REPL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.